8 completed, 4 recruiting, 4 terminated, 2 active not recruiting. 11 Phase 2, 7 Phase 1, 6 Phase 3.
Follow Standard of Care Chemotherapy: new trials by email Literature Review of Standard of Care Chemotherapy trials Research Report on Standard of Care Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer PF-08634404, Pembrolizumab, Standard of Care Chemotherapy - Endometrial Neoplasms, Endometrial Cancer | Phase 3 | Not yet recruiting | Pfizer | 600 | 2026-10-09 | 2026-10-08 |
| Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma Standard of care chemotherapy, LNSC - Esophageal Adenocarcinoma, Esophageal Cancer | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 40 | 2026-06-10 | 2026-08-18 |
| Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) Standard of Care Chemotherapy, Tarlatamab - Neuroendocrine Carcinoma | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 129 | 2026-02-06 | 2026-02-11 |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 148 | 2025-10-24 | 2026-10-05 |
| Kaposi Sarcoma Chemotherapy and Research (KS-CARE) standard of care chemotherapy - Kaposi Sarcoma, HIV | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 127 | 2023-04-25 | 2026-02-05 | |
| A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) IMU-131, Ramucirumab plus Paclitaxel, Pembrolizumab - Gastric Cancer, Cancer of Stomach | Phase 2 | Terminated | Imugene Limited | 7 | 2022-08-17 | 2025-05-11 |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), Lobectomy - Metastatic Cancer, Foregut Carcinoid Tumor | Phase 2 | Withdrawn | University of Chicago | 2022-05-19 | 2024-07-31 | |
| Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy - Acute Myeloid Leukemia | Phase 3 | Withdrawn | University Hospital Heidelberg | 2022-05-01 | 2022-05-25 | |
| A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis Birtamimab, Placebo, Standard of Care Chemotherapy - Light Chain (AL) Amyloidosis | Phase 3 | Terminated | Prothena Biosciences Ltd. | 208 | 2021-08-30 | 2025-12-16 |
| CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy - Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 19 | 2021-01-14 | 2026-02-19 |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy - Salivary Gland Cancer, HER2 Gene Mutation | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-12-24 | 2026-04-13 |
| Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy - Locally Advanced Non-Small Cell Lung Cancer | Phase 1 | Completed | University of Oxford | 21 | 2020-12-07 | 2026-01-29 |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3 - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB | Phase 1 | Terminated | Imugene Limited | 24 | 2020-11-30 | 2026-03-25 |
| Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Atezolizumab, Standard of Care Chemotherapy, Tiragolumab - Non-Small Cell Lung Cancer, Solid Tumor | Phase 2 | Completed | SCRI Development Innovations, LLC | 46 | 2019-08-30 | 2025-08-27 |
| DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer DCVAC/OvCa, Standard of Care Chemotherapy - Ovarian Cancer Recurrent | Phase 2 | Completed | SOTIO a.s. | 33 | 2017-11-23 | 2021-04-21 |
| A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine. - Gastrointestinal Neoplasms, Adenocarcinoma | Phase 1 / Phase 2 | Completed | Imugene Limited | 64 | 2017-08-30 | 2025-04-16 |
| Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors mRNA-4157, Pembrolizumab, SoC Treatment - Solid Tumors | Phase 1 | Active not recruiting | ModernaTX, Inc. | 161 | 2017-08-14 | 2026-09-03 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Exceptional Responders With Solid Tumor Cancer to Chemotherapy Standard of Care Chemotherapy - Solid Tumor Neoplasms | Enrolling by invitation | Adera Labs, LLC | 250 | 2015-10-01 | 2023-02-01 | |
| Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer DCVAC add on to SOC, DCVAC and immune enhancers add on to SOC, Standard of Care Chemotherapy - Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | SOTIO a.s. | 105 | 2014-12-01 | 2022-05-04 |
Showing 20 of 22. Sign in to see all of them.
Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3) · Fallopian Tube Neoplasms (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Peritoneal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Amyloidosis (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Pancreatic Ductal (1) · Endometrial Neoplasms (1)
Imugene Limited (3) · SOTIO a.s. (2) · Adera Labs, LLC (1) · Amgen (1) · AstraZeneca (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Eli Lilly and Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · ModernaTX, Inc. (1) · Pfizer (1) · Prothena Biosciences Ltd. (1) · SCRI Development Innovations, LLC (1)
United States (12) · Australia (6) · Taiwan (5) · United Kingdom (5) · Czechia (4) · Japan (4) · Canada (3) · France (3) · Israel (3) · South Korea (3) · Austria (2) · Belgium (2) · Germany (2) · Greece (2) · Ireland (2)
Brian McCarthy, PhD (1) · Dirk Dittmer, PhD (1) · Geoffrey Higgins (1) · Glenn J Hanna, MD (1) · Harald Fricke, MD, PhD (1) · Joseph Pidala, MD, PhD (1) · Kiran Turaga, MD (1) · Maheswari Senthil (1) · Melissa Johnson, MD (1) · Richard F Schlenk, Prof Dr (1) · Tilak Shah, MD (1) · Tomas Scheiner (1)
PMID 31931024, PMID 32289160, PMID 33542479, PMID 33879458, PMID 34161631, PMID 35622074, PMID 35898703, PMID 37366170, PMID 37489066, PMID 38600883, PMID 39028916, PMID 39485256
2014 (1), 2017 (1), 2023 (1), U10CA180820 (1), U54CA254564 (1)